Agenda

On 22-23 September 2021 the first TOPX Summit takes place in Leiden, the Netherlands. During these 2 days you will get to meet and learn from some of the most inspiring and successful female leaders in the Life Sciences Sector. The programme, organised by and for ambitious women in Life Sciences, will cover deep dive workshops, interactive discussions, personal stories and lessons learned, one-on-one speed dates and many networking moments. We specifically also welcome men for the 1st general day of the summit to join the discussion! So, join us for a unique programme that will support and empowerment you in your efforts to rise to the top.

The ceremony will commence at 15.30 pm CEST on September 22, 2021 at the BioPartner Buidling 1 and a tour will follow at the BioPartner Buidling 2.

Please fill in your registration before 12:00 CEST, September 14, 2021.

On 22-23 September 2021 the first TOPX Summit takes place in Leiden, the Netherlands. During these 2 days you will get to meet and learn from some of the most inspiring and successful female leaders in the Life Sciences Sector. The programme, organised by and for ambitious women in Life Sciences, will cover deep dive workshops, interactive discussions, personal stories and lessons learned, one-on-one speed dates and many networking moments. We specifically also welcome men for the 1st general day of the summit to join the discussion! So, join us for a unique programme that will support and empowerment you in your efforts to rise to the top.

knowledge for growth is Europe's finest life sciences conference and debuts this year as a hybrid event.

THREE DAYS FULL OF HIGH-QUALITY CONTENT & AMPLE NETWORKING OPPORTUNITIES

The conference features an exciting programme providing vital insight into the global life sciences’ landscape, one-to-one partnering, a trade fair and more!

The cream of the Belgian life sciences community will attend the 17th edition of flanders.bio’s annual knowledge for growth business conference, attracting decision makers from biotech, pharma and medtech, agricultural and chemical industry as well as investors, universities, topnotch research institutes, policymakers and competence providers.

knowledge for growth is Europe's finest life sciences conference and debuts this year as a hybrid event.

THREE DAYS FULL OF HIGH-QUALITY CONTENT & AMPLE NETWORKING OPPORTUNITIES

The conference features an exciting programme providing vital insight into the global life sciences’ landscape, one-to-one partnering, a trade fair and more!

The cream of the Belgian life sciences community will attend the 17th edition of flanders.bio’s annual knowledge for growth business conference, attracting decision makers from biotech, pharma and medtech, agricultural and chemical industry as well as investors, universities, topnotch research institutes, policymakers and competence providers.

knowledge for growth is Europe's finest life sciences conference and debuts this year as a hybrid event.

THREE DAYS FULL OF HIGH-QUALITY CONTENT & AMPLE NETWORKING OPPORTUNITIES

The conference features an exciting programme providing vital insight into the global life sciences’ landscape, one-to-one partnering, a trade fair and more!

The cream of the Belgian life sciences community will attend the 17th edition of flanders.bio’s annual knowledge for growth business conference, attracting decision makers from biotech, pharma and medtech, agricultural and chemical industry as well as investors, universities, topnotch research institutes, policymakers and competence providers.

This event is scheduled for Friday, October 1, from 10:00AM to 5:00PM, followed by networking cocktail hour. Breakfast and a lunch will be provided to attendees.

The seminar will focus on translational research in the fields of immunogenicity and tolerance, with case studies touching on vaccines and biologics.

Special Guest Speakers will include:

Annie De Groot, MD
Research Professor, Center for Vaccines and Immunology, University of Georgia
CEO/CSO, EpiVax, Inc.

Amy Rosenberg, MD
Senior Director of Immunology and Protein Therapeutics, EpiVax, Inc.

Interested in presenting at our seminar? Contact kporter@epivax.com.

Interested in attending our seminar? Register here!

MORNING SESSIONS
9:30–10:30 CET
OPENING: Delivering the Green Deal – industrial biotechnology into business
Part I
10:30–11:00 CET
Break
11:00–12:00 CET
OPENING: Delivering the Green Deal – industrial biotechnology into business
Part II
from 12:00 CET Virtual 1:1 Partnering Meetings
12:00–13:00 CET
Lunch Break
AFTERNOON SESSIONS
13:00–14:30 CET
Parallel Session A

Food, feed, nutrition: Towards a sustainable food system approach
Part I
Parallel Session B

Sustainable materials: Bio-based innovation and circular wins
Part I
Parallel Session C

Executive round table
14:30–15:30 CET
Coffee Break
15:30–17:00 CET
Parallel Session A

Food, feed, nutrition: Towards a sustainable food system approach
Part II
Parallel Session B

Sustainable materials: Bio-based innovation and circular wins
Part II
Parallel Session C

Sustainable cities: From ideas to action
17:00–18:00 CET
Start-up pitches in the start-up village
Part I
From 18:30 CET
Evening reception supported by the local host

ALL DAY Virtual 1:1 Partnering Meetings
MORNING SESSIONS

9:30–10:30 CET
Parallel Session A
Sustainable finance: Building value and enabling scale-up
Part I
Parallel Session B
Bioprocesses: Next-generation impact on industrial manufacturing
Part I
Parallel Session C
Workshops/Roundtables

10:30–11:00 CET
Break

11:00–12:15 CET
Parallel Session A
Sustainable finance: Building value and enabling scale-up
Part II
Parallel Session B
Bioprocesses: Next-generation impact on industrial manufacturing
Part II
Parallel Session C
Workshops/Roundtables

12:15–13:30 CET
Lunch Break

AFTERNOON SESSIONS
13:30–14:30 CET
OUTLOOK: The pathway to the future for Industrial Biotechnology
14:45–15:30 CET
Start-up pitches in the start-up village
Part II

15:30–16:30 CET
Closing Reception & Outlook EFIB 2022

COVID-19 heeft ons hardhandig duidelijk gemaakt hoe belangrijk het is om je gezondheidssysteem goed op orde te hebben. Wat leren we hiervan? En zijn we klaar voor volgende uitdagingen, zoals nieuwe virussen en groeiende antibioticaresistentie?

Hoe maken we van ons land het Boston aan de Noordzee? Daarover gaat de eerste editie van de VIG Medicijndialoog op donderdag 7 oktober. Een sterke geneesmiddelensector maakt ons land gezonder, weerbaarder en welvarender.

Inspiratieworkshops

Het programma bestaat uit een ochtend- en een middagsessie. In de ochtend, van 11.00 tot 12.00 uur, zijn er vier digitale inspiratieworskhops met verschillende thema’s en sprekers:

Workshop ‘Langjarig overheidscommitment’ onder leiding van Clémence Ross (ambassadeur LSH-sector)
Workshop ‘Nieuwe laboratoria van wereldklasse’ onder leiding van Ida Haisma (directeur Leiden Bio Science Park)
Workshop ‘Durf concurrerend te zijn’ onder leiding van Carmen van Vilsteren (boegbeeld LSH-sector)
Workshop ‘Ondernemerschap en vestigingsklimaat’ onder leiding van Thomas Grosfeld (VNO-NCW)
De uitkomsten van de workshops dienen als input voor plenaire deel dat plaatsvindt in de middag.

Keynote speaker Jan Peter Balkenende

Vanaf 15.30 uur vindt het tweede deel van de Medicijndialoog plaats. Voormalig minister-president prof. dr. Jan Peter Balkenende opent het plenaire deel met een beschouwing op de geopolitieke situatie in de wereld en de uitdagingen voor Nederland en Europa. Moet gezondheid nog wel een nationale competentie blijven en moeten we minder afhankelijk worden van India en China? En welke gevolgen heeft dit voor de Nederlandse geneesmiddelensector?

Na deze keynote speech, vindt een paneldebat plaats, waaraan ook workshopleiders Clémence Ross, Ida Haisma, Carmen van Vilsteren en Thomas Grosfeld zullen deelnemen. Ook CDA-Kamerlid Mustafa Amhaouch zal een bijdrage leveren aan de discussie. Aan de verdere invulling van het programma wordt nog gewerkt.

Aanmelden

Het plenaire middagdeel wordt live uitgezonden vanuit Nieuwspoort, Den Haag. U kunt hieraan online deelnemen en vragen stellen via de chat. Bij aanmelding kunt u meteen aangeven bij welke digitale workshop u in de ochtend wilt aanhaken. Het is ook mogelijk om alleen het plenaire deel óf een workshop te volgen. Het programma eindigt om 17.00 uur. Na aanmelding ontvangt u van ons meer informatie en een toegangscode!

Deze bijeenkomst is bedoeld voor Human Capital verantwoordelijke en onderwijs en faculteit managers die gevestigd zijn op het Leiden Bio Science Park of die behoren bij het Leiden Bio Science Park cluster

De Human Capital Netwerk bijeenkomsten

Tijdens de Human Capital Network bijeenkomsten bouwen wij aan een community op het Leiden Bio Science Park. Samen zetten we de Human Capital Agenda op voor het Leiden Bio Science Park en werken we hieraan. De bijeenkomsten zijn in algemeenheid bedoeld om met elkaar vraagstukken of knelpunten te bespreken en te behandelen. Dit doen wij door te luisteren naar inspirerende sprekers, actief met elkaar te discussiëren en kennis met elkaar te delen.

Vragen?

Aarzel niet om contact op te nemen met Ineke Bakkeren. ibakkeren@lbsp.nl

The first edition of Access Biotech China (ABC) is planned on 14-15 October 2021 as an hybrid event. Access Biotech China aims to help European Life Sciences & Health companies to explore and seize the many opportunities that the Chinese biotech sector has to offer. The focus will not only be on accessing the market and entering partnering opportunities, but also on getting access to the Chinese financial market and investors.

China is rapidly becoming increasingly attractive for biotechs looking for additional investment, partnerships and customers. Not only does China have a massive population and a correspondingly large patient group, the phenomenal economic growth, government reforms and huge investments have turned the Chinese biopharmaceutical market into the second largest in the world with $137 billion in sales last year.

The importance of the biotech industry has been recognised by the Chinese Government. It has recently introduced changes in regulations to make it much easier and quicker for drugs developed by foreign companies to be approved and sold in China, but also for Chinese VCs to seek out promising foreign investments. While there are still more cross-border investments from China to the US than there are between China and Europe, interest in European biotech is growing rapidly.

Due to the complexity of policies on different market segments, the vastness of the country and the different (business) culture and language, it can almost seem like a mission impossible to enter the Chinese market successfully for foreign companies with limited or no experience in doing business there. Entry of the Chinese market requires tailor-made strategies. There is not a 'one-size-fits-all' approach.

Access Biotech China aims to give you the abc of how to take the first steps to enter the Chinese biotech sector. Besides giving you insight in the opportunities that China has to offer for you as a biotech company, it will also give you insight in some of the key challenges and provide you with practical recommendations that will help you to develop a China market entry strategy. In addition, ABC will bring you in touch with organisations that can help you achieve that.

The first edition of Access Biotech China (ABC) is planned on 14-15 October 2021 as an hybrid event. Access Biotech China aims to help European Life Sciences & Health companies to explore and seize the many opportunities that the Chinese biotech sector has to offer. The focus will not only be on accessing the market and entering partnering opportunities, but also on getting access to the Chinese financial market and investors.

China is rapidly becoming increasingly attractive for biotechs looking for additional investment, partnerships and customers. Not only does China have a massive population and a correspondingly large patient group, the phenomenal economic growth, government reforms and huge investments have turned the Chinese biopharmaceutical market into the second largest in the world with $137 billion in sales last year.

The importance of the biotech industry has been recognised by the Chinese Government. It has recently introduced changes in regulations to make it much easier and quicker for drugs developed by foreign companies to be approved and sold in China, but also for Chinese VCs to seek out promising foreign investments. While there are still more cross-border investments from China to the US than there are between China and Europe, interest in European biotech is growing rapidly.

Due to the complexity of policies on different market segments, the vastness of the country and the different (business) culture and language, it can almost seem like a mission impossible to enter the Chinese market successfully for foreign companies with limited or no experience in doing business there. Entry of the Chinese market requires tailor-made strategies. There is not a 'one-size-fits-all' approach.

Access Biotech China aims to give you the abc of how to take the first steps to enter the Chinese biotech sector. Besides giving you insight in the opportunities that China has to offer for you as a biotech company, it will also give you insight in some of the key challenges and provide you with practical recommendations that will help you to develop a China market entry strategy. In addition, ABC will bring you in touch with organisations that can help you achieve that.